Hyaluronic Acid Hydrogel Containing Resveratrol-Loaded Chitosan Nanoparticles as an Adjuvant in Atopic Dermatitis Treatment.
anti-inflammatory
antioxidant
atopic dermatitis
chitosan
hyaluronic acid
hydrogel
nanoparticles
resveratrol
Journal
Journal of functional biomaterials
ISSN: 2079-4983
Titre abrégé: J Funct Biomater
Pays: Switzerland
ID NLM: 101570734
Informations de publication
Date de publication:
31 Jan 2023
31 Jan 2023
Historique:
received:
17
12
2022
revised:
14
01
2023
accepted:
29
01
2023
entrez:
24
2
2023
pubmed:
25
2
2023
medline:
25
2
2023
Statut:
epublish
Résumé
Atopic dermatitis (AD) is a common disease-causing skin inflammation, redness, and irritation, which can eventually result in infection that drastically impacts patient quality of life. Resveratrol (Res) is a natural phytochemical famed for its excellent anti-inflammatory and antioxidant activities. However, it is poorly bioavailable. Thus, a drug delivery system is needed to enhance in vivo bioactivity. Herein, we report the preparation of hyaluronic acid (HA) hydrogels containing resveratrol-loaded chitosan (CS) nanoparticles, their physicochemical analysis, and their potential therapeutic effects in the treatment of AD. Positively charged CS nanoparticles prepared by tripolyphosphate (TPP) gelation showed sizes ranging from 120 to around 500 nm and Res encapsulation efficiency as high as 80%. Embedding the nanoparticles in HA retarded their hydrolytic degradation and also slowed resveratrol release. Resveratrol released from nanoparticle-loaded hydrogel counteracted the oxidative damage induced by ROS generation in TNF-α/INF-γ-treated human keratinocytes (HaCaT) used as an AD in vitro model. Moreover, pre-treatment with Res@gel reduced secretion and gene expression of proinflammatory cytokines in HaCaT cells. The physicochemical analysis and in vitro assay confirmed that the formulated hydrogel could be considered an efficient and sustained resveratrol delivery vector in AD treatment.
Identifiants
pubmed: 36826881
pii: jfb14020082
doi: 10.3390/jfb14020082
pmc: PMC9959248
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Allianz Industrie Forschung (AiF)
ID : ZF4025045AJ9
Organisme : AND FONDECYT REGULAR
ID : 1221609
Organisme : : Sviluppo di nanotecnologie Orientate alla Rigenerazione e Ricostruzione tissutale, Implanto-lo-gia e Sensoristica in Odontoiatria/oculistica (SORRISO)
ID : PON 03 PE_00110_1/ptd1_000410
Organisme : POR Campania FESR 2014_2020 "Tecnologie abilitanti per la sintesi eco-sostenibile di nuovi ma-teriali per la restaurativa dentale" - ABILTECH; EU funding within the Horizon 2020 Program, under the MSCA-RISE 2016 Project "VAHVISTUS"
ID : 734759
Références
Molecules. 2019 Jul 15;24(14):
pubmed: 31311176
Drug Deliv Transl Res. 2017 Oct;7(5):750-760
pubmed: 28597122
J Dent Res. 2015 Aug;94(8):1099-105
pubmed: 25924857
Indian Dermatol Online J. 2014 Oct;5(4):416-25
pubmed: 25396122
Colloids Surf B Biointerfaces. 2014 Feb 1;114:36-44
pubmed: 24161504
Polymers (Basel). 2020 Aug 11;12(8):
pubmed: 32796708
Carbohydr Polym. 2014 Aug 8;108:321-30
pubmed: 24751280
Curr Med Res Opin. 2010 Mar;26(3):633-40
pubmed: 20070141
Biomaterials. 2009 May;30(13):2499-506
pubmed: 19167750
Eur J Pharmacol. 2021 Oct 5;908:174380
pubmed: 34303665
Int J Mol Sci. 2022 Feb 14;23(4):
pubmed: 35216228
Polymers (Basel). 2022 Aug 23;14(17):
pubmed: 36080515
Polymers (Basel). 2018 Jun 25;10(7):
pubmed: 30960626
Evid Based Complement Alternat Med. 2015;2015:676897
pubmed: 26257817
J Adv Res. 2017 May;8(3):217-233
pubmed: 28239493
Oxid Med Cell Longev. 2016;2016:2721469
pubmed: 27006746
Drug Deliv Transl Res. 2019 Apr;9(2):520-533
pubmed: 29488170
Carbohydr Polym. 2020 Apr 1;233:115839
pubmed: 32059889
J Biomed Res. 2021 Jun 16;35(6):448-458
pubmed: 34497158
J Dermatol Sci. 2019 Oct;96(1):2-7
pubmed: 31455506
Molecules. 2020 Nov 30;25(23):
pubmed: 33266220
Carbohydr Polym. 2018 Sep 1;195:631-641
pubmed: 29805021
Int J Mol Sci. 2020 Jan 29;21(3):
pubmed: 32013257
J Food Drug Anal. 2021 Mar 15;29(1):15-38
pubmed: 35696226
J Physiol. 1953 Feb 27;119(2-3):244-52
pubmed: 13035748
Cells. 2021 Nov 09;10(11):
pubmed: 34831319
Drug Deliv Transl Res. 2017 Feb;7(1):37-52
pubmed: 27981502
Biomed Mater. 2019 Mar 07;14(3):035003
pubmed: 30690433
Chirality. 2018 Nov;30(11):1206-1214
pubmed: 30199113
Mar Drugs. 2011;9(9):1664-1681
pubmed: 22131964
Colloids Surf B Biointerfaces. 2019 Aug 1;180:127-140
pubmed: 31035056
J Cosmet Dermatol. 2011 Sep;10(3):185-8
pubmed: 21896129
Wounds. 2019 Nov;31(11):279-284
pubmed: 31730508
Antioxidants (Basel). 2020 Feb 26;9(3):
pubmed: 32111015
Carbohydr Polym. 2020 Feb 15;230:115627
pubmed: 31887941
Antioxidants (Basel). 2022 Jun 20;11(6):
pubmed: 35740107
Nat Rev Drug Discov. 2022 Jan;21(1):21-40
pubmed: 34417579
Macromol Biosci. 2022 Dec;22(12):e2200111
pubmed: 35866647
Eur J Pharm Sci. 2015 Jan 23;66:20-8
pubmed: 25277680
J Clin Med. 2021 Jun 11;10(12):
pubmed: 34208041
PeerJ. 2016 Mar 31;4:e1889
pubmed: 27069818
Int J Pharm. 2020 Jul 30;585:119507
pubmed: 32512223
J Ethnopharmacol. 2008 Jan 17;115(2):249-56
pubmed: 18037253
Adv Mater. 2011 Mar 25;23(12):H41-56
pubmed: 21394792
Molecules. 2022 Mar 28;27(7):
pubmed: 35408602
J Invest Surg. 2022 May;35(5):1135-1144
pubmed: 34670455
Nanomaterials (Basel). 2020 Jun 16;10(6):
pubmed: 32560209
Ann Transl Med. 2021 Jul;9(14):1152
pubmed: 34430593
Drug Deliv. 2022 Dec;29(1):1212-1231
pubmed: 35403519
Int J Nanomedicine. 2017 Dec 22;13:129-142
pubmed: 29317821
Drug Deliv Transl Res. 2019 Apr;9(2):469-481
pubmed: 29159691
Adv Wound Care (New Rochelle). 2014 Aug 1;3(8):511-529
pubmed: 25126472
Int Immunopharmacol. 2014 Dec;23(2):617-23
pubmed: 25466270